In summary, we here provide proof of principle for the efficacy of CD38-specific HLE-nano-BiKEs in vitro and ex vivo, warranting further preclinical evaluation in vivo of their therapeutic potential for the treatment of multiple myeloma. The gene discussed is CD38; the disease is plasma cell myeloma.